StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
June 24, 2024 7:28 AM
Stifel analyst Paul Matteis reiterated a Buy rating and $247.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst comments "We ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Alnylam Pharmaceuticals (ALNY) PT Raised to $250 at Morgan Stanley
June 24, 2024 12:28 PM
RBC Capital Positive on Alnylam Pharmaceuticals (ALNY): 'HELIOS-B Hits Convincingly Across the Board, Materially Exceeding Expectations'
June 24, 2024 11:38 AM
Alnylam Pharma (ALNY) to Resume Trading at 7:30 a.m.
June 24, 2024 7:11 AM
BridgeBio Pharma (BBIO) Trades Lower After Alnylam Pharma (ALNY) Reports Positive Data
June 24, 2024 7:10 AM
Alnylam Pharma (ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran
June 24, 2024 7:00 AM
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population
June 24, 2024 7:00 AM
